Table. 2.

Transplant outcomes

Variable Patient no.

1 2 3 4 5 6 7 8 9
Transplantation
Age at transplantation (yr) 33 13 10 26 20 51 11 10 30
Donor type LD LD LD DD LD DD LD LD LD
Donor age (yr) 60 41 42 16 49 65 38 42 57
HLA mismatch 3 3 2 0 1 5 3 2 3
Immunosuppression CsA, Pd, (+MMF) CsA, Pd, (–AZA) TAC, Pd, MMF TAC, Pd, MMF TAC, Pd, MMF TAC, Pd, MMF TAC, Pd, MMF TAC, Pd, MMF TAC, Pd, MMF
Outcome
Follow-up (mo) 341 259 185 175 148 148 126 49 2
Serum creatinine (mg/dL) 5.64 0.78 6.78 0.72 0.95 1.38 1.36 5.39 1.06
Acute rejection No No No No No Yes No Yes No
Admission for febrile UTI 3 3 3 4 0 0 0 5 0
Pathogens (>105 CFU in urine) Escherichia coli, Pseudomonas aeruginosa Klebsiella pneumoniae E. coliE. aerogenesM. morganii K. pneumoniaeEnterococcus FaecalisEnterobacter cloacae None None None E. coliK. pneumoniaeProteus penerri None
Graft failure Yes No Yes No No No No Yes No
Graft survival time (mo) 302 259 107 175 148 148 126 35 2

Borderline change on protocol biopsy without renal dysfunction.

LD, living donor; DD, deceased donor; HLA, human leukocyte antigen; CsA, cyclosporine A; Pd, prednisolone; MMF, mycophenolate mofetil; AZA, azathioprine; TAC, tacrolimus; UTI, urinary tract infection; CFU, colony-forming unit.

Korean J Transplant 2020;34:238~243 https://doi.org/10.4285/kjt.20.0046
© Korean Journal of Transplantation